Alexion Pharmaceuticals
(NASDAQ: ALXN)
+1.07
+1.17%
Alexion Pharmaceuticals, a large-cap growth company in the health care sector, is expected to significantly outperform the market over the next six months with average risk.
10 is the best possible rating.
Earnings growth in the past year has accelerated rapidly compared to earnings growth in the past three years. Positive
The price-to-sales multiple is significantly higher than the average for all stocks in the StockScouter universe. Very positive for a medium- to large-sized company like ALXN
ConThe price-to-earnings multiple is higher than the average for all stocks in the StockScouter universe. Negative
One or more analysts has significantly decreased quarterly earnings estimates for ALXN. Negative
The most recent quarterly earnings report was approximately equal to or higher than analysts’ consensus forecast, but not to a degree that is predictive of future returns. Neutral
Earnings growth in the past year has accelerated rapidly compared to earnings growth in the past three years. Positive
One or more analysts has significantly decreased quarterly earnings estimates for ALXN. Negative
Two or more executives, directors or major shareholders sold a small number of shares recently. Negative
Shares are under heavy accumulation by financial institutions. Positive for large companies like ALXN
The price-to-earnings multiple is higher than the average for all stocks in the StockScouter universe. Negative
The price-to-sales multiple is significantly higher than the average for all stocks in the StockScouter universe. Very positive for a medium- to large-sized company like ALXN
The ratio of ALXN's price-to-earnings multiple to its five-year growth rate is about the same or slightly above the average of all stocks in the StockScouter universe. Positive
The StockScouter measure of relative price change and consistency is low. Negative
Previous day's closing price for ALXN was slightly below its 50-day moving average. Negative
data provided by Verus Analytics
Learn more about the StockScouter rating system.
Page generated 6/19/2013 6:16 AM ET
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
